Roivant Sciences Ltd.
ROIV
Rankning i aktier
#980
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Aktiekurs
$33.73
Senast synkroniserad: 2026-07-31
Marknadsvärde
$24.37B
Förändring (1 dag)
-2.28%
Förändring (1 år)
95.44%
Land
GB
Handel Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
EPS för Roivant Sciences Ltd. (ROIV)
EPS per June 2026 TTM: $-0.38
Enligt Roivant Sciences Ltd.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-0.38. Vid slutet av 2024 hade bolaget ett EPS på $5.55, en ökning jämfört med EPS från 2023 som var $-1.42.
EPS-historik för Roivant Sciences Ltd. från 2020 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-0.38 | 58.33% |
| 2025 | $-0.24 | -104.32% |
| 2024 | $5.55 | -490.85% |
| 2023 | $-1.42 | 12.70% |
| 2022 | $-1.26 | 6.78% |
| 2021 | $-1.18 | -167.43% |
| 2020 | $1.75 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -4,657.89% |
US
|
|
| $-7.98 | 2,000.00% |
US
|
|
| $-5.29 | 1,292.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,400.00% |
NL
|
